Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2022

20.01.2021 | Original Article

Disease-Based Risk Stratification of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis for Common Bile Duct Stones

verfasst von: Hirokazu Saito, Masafumi Sakaguchi, Yoshihiro Kadono, Takashi Shono, Kentaro Kamikawa, Atsushi Urata, Jiro Nasu, Haruo Imamura, Ikuo Matsushita, Tatsuyuki Kakuma, Shuji Tada

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Risk stratification of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) for common bile duct (CBD) stones is needed for clinicians to adequately explain to patients regarding the risk of PEP in advance of ERCP and to proactively take preventive measures in high-risk patients.

Aims

To stratify the risk of PEP for CBD stones based on CBD-related diseases.

Methods

A total of 1551 patients with naïve papilla who underwent ERCP for CBD stones were divided into three groups: Group A: asymptomatic CBD stones, Group B: obstructive jaundice and elevated liver test values without cholangitis, and Group C: mild, moderate, and severe cholangitis. We stratified the risk of PEP by comparing its incidence among the three groups using the Holm’s method. Furthermore, we performed one-to-one propensity score matching between Group A and the other groups to examine the risk of PEP in Group A.

Results

The incidence rates in Groups A, B, and C were 13.7%, 7.3%, and 1.8%, respectively. The Holm-adjusted p values between Groups A and B, Groups A and C, and Groups B and C were 0.023, < 0.001, and < 0.001, respectively. Propensity score matching revealed that the incidence of PEP was significantly more in Group A than in the other groups (13.3% vs. 1.5%; p < 0.001).

Conclusions

The risk of PEP for CBD stones was stratified into low risk (Group C), intermediate risk (Group B), and high risk (Group A). This simple disease-based risk stratification may be useful to predict the risk of PEP in advance of ERCP.
Literatur
1.
Zurück zum Zitat Williams E, Beckingham I, El Sayed G et al. Updated guideline on the management of common bile duct stones (CBDS). Gut. 2017;66:765–782CrossRef Williams E, Beckingham I, El Sayed G et al. Updated guideline on the management of common bile duct stones (CBDS). Gut. 2017;66:765–782CrossRef
2.
Zurück zum Zitat Buxbaum JL, Abbas Fehmi SM, Sultan S et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019;89:1075–1105CrossRef Buxbaum JL, Abbas Fehmi SM, Sultan S et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019;89:1075–1105CrossRef
3.
Zurück zum Zitat Manes G, Paspatis G, Aabakken L et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51:472–491CrossRef Manes G, Paspatis G, Aabakken L et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51:472–491CrossRef
4.
Zurück zum Zitat Tazuma S, Unno M, Igarashi Y et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300CrossRef Tazuma S, Unno M, Igarashi Y et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300CrossRef
5.
Zurück zum Zitat Chandrasekhara V, Khashab MA, Muthusamy VR et al. Adverse events associated with ERCP. Gastrointest Endosc. 2017;85:32–47CrossRef Chandrasekhara V, Khashab MA, Muthusamy VR et al. Adverse events associated with ERCP. Gastrointest Endosc. 2017;85:32–47CrossRef
6.
Zurück zum Zitat Saito H, Koga T, Sakaguchi M et al. Post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with asymptomatic common bile duct stones. J Gastroenterol Hepatol. 2019;34:1153–1159CrossRef Saito H, Koga T, Sakaguchi M et al. Post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with asymptomatic common bile duct stones. J Gastroenterol Hepatol. 2019;34:1153–1159CrossRef
7.
Zurück zum Zitat Dumonceau JM, Kapral C, Aabakken L et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2020;52:127–149CrossRef Dumonceau JM, Kapral C, Aabakken L et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2020;52:127–149CrossRef
8.
Zurück zum Zitat Mine T, Morizane T, Kawaguchi Y et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol. 2017;52:1013–1022CrossRef Mine T, Morizane T, Kawaguchi Y et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol. 2017;52:1013–1022CrossRef
9.
Zurück zum Zitat Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417–423CrossRef Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417–423CrossRef
10.
Zurück zum Zitat Wang P, Li ZS, Liu F et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009;104:31–40CrossRef Wang P, Li ZS, Liu F et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009;104:31–40CrossRef
11.
Zurück zum Zitat Kiriyama S, Kozaka K, Takada T et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25:17–30CrossRef Kiriyama S, Kozaka K, Takada T et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25:17–30CrossRef
12.
Zurück zum Zitat Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71:446–454CrossRef Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71:446–454CrossRef
13.
Zurück zum Zitat Chan AO, Jim MH, Lam KF et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007;298:1412–1419CrossRef Chan AO, Jim MH, Lam KF et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007;298:1412–1419CrossRef
14.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–458CrossRef Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–458CrossRef
15.
Zurück zum Zitat Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434CrossRef Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434CrossRef
17.
Zurück zum Zitat Xu XD, Qian JQ, Dai JJ, Sun ZX. Endoscopic treatment for choledocholithiasis in asymptomatic patients. J Gastroenterol Hepatol. 2020;35:165–169CrossRef Xu XD, Qian JQ, Dai JJ, Sun ZX. Endoscopic treatment for choledocholithiasis in asymptomatic patients. J Gastroenterol Hepatol. 2020;35:165–169CrossRef
18.
Zurück zum Zitat Hakuta R, Hamada T, Nakai Y et al. Natural history of asymptomatic bile duct stones and association of endoscopic treatment with clinical outcomes. J Gastroenterol. 2020;55:78–85CrossRef Hakuta R, Hamada T, Nakai Y et al. Natural history of asymptomatic bile duct stones and association of endoscopic treatment with clinical outcomes. J Gastroenterol. 2020;55:78–85CrossRef
19.
Zurück zum Zitat Ammori BJ, Birbas K, Davides D et al. Routine vs “on demand” postoperative ERCP for small bile duct calculi detected at intraoperative cholangiography. Clinical evaluation and cost analysis. Surg Endosc. 2000;14:1123–1126CrossRef Ammori BJ, Birbas K, Davides D et al. Routine vs “on demand” postoperative ERCP for small bile duct calculi detected at intraoperative cholangiography. Clinical evaluation and cost analysis. Surg Endosc. 2000;14:1123–1126CrossRef
20.
Zurück zum Zitat Collins C, Maguire D, Ireland A et al. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg. 2004;239:28–33CrossRef Collins C, Maguire D, Ireland A et al. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg. 2004;239:28–33CrossRef
21.
Zurück zum Zitat Caddy GR, Kirby J, Kirk SJ et al. Natural history of asymptomatic bile duct stones at time of cholecystectomy. Ulster Med J. 2005;74:108–112PubMedPubMedCentral Caddy GR, Kirby J, Kirk SJ et al. Natural history of asymptomatic bile duct stones at time of cholecystectomy. Ulster Med J. 2005;74:108–112PubMedPubMedCentral
22.
Zurück zum Zitat Moller M, Gustafsson U, Rasmussen F et al. Natural course vs interventions to clear common bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks). JAMA Surg. 2014;149:1008–1013CrossRef Moller M, Gustafsson U, Rasmussen F et al. Natural course vs interventions to clear common bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks). JAMA Surg. 2014;149:1008–1013CrossRef
23.
Zurück zum Zitat Frossard JL, Hadengue A, Amouyal G et al. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. Gastrointest Endosc. 2000;51:175–179CrossRef Frossard JL, Hadengue A, Amouyal G et al. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. Gastrointest Endosc. 2000;51:175–179CrossRef
24.
Zurück zum Zitat Friedland S, Soetikno RM, Vandervoort J, Montes H, Tham T, Carr-Locke DL. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy. 2002;34:483–488CrossRef Friedland S, Soetikno RM, Vandervoort J, Montes H, Tham T, Carr-Locke DL. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy. 2002;34:483–488CrossRef
25.
Zurück zum Zitat Jeurnink SM, Siersema PD, Steyerberg EW et al. Predictors of complications after endoscopic retrograde cholangiopancreatography: a prognostic model for early discharge. Surg Endosc. 2011;25:2892–2900CrossRef Jeurnink SM, Siersema PD, Steyerberg EW et al. Predictors of complications after endoscopic retrograde cholangiopancreatography: a prognostic model for early discharge. Surg Endosc. 2011;25:2892–2900CrossRef
26.
Zurück zum Zitat DiMagno MJ, Spaete JP, Ballard DD, Wamsteker EJ, Saini SD. Risk models for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP): smoking and chronic liver disease are predictors of protection against PEP. Pancreas. 2013;42:996–1003CrossRef DiMagno MJ, Spaete JP, Ballard DD, Wamsteker EJ, Saini SD. Risk models for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP): smoking and chronic liver disease are predictors of protection against PEP. Pancreas. 2013;42:996–1003CrossRef
Metadaten
Titel
Disease-Based Risk Stratification of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis for Common Bile Duct Stones
verfasst von
Hirokazu Saito
Masafumi Sakaguchi
Yoshihiro Kadono
Takashi Shono
Kentaro Kamikawa
Atsushi Urata
Jiro Nasu
Haruo Imamura
Ikuo Matsushita
Tatsuyuki Kakuma
Shuji Tada
Publikationsdatum
20.01.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06825-6

Weitere Artikel der Ausgabe 1/2022

Digestive Diseases and Sciences 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.